The medication most likely responsible for the patient's recent rapid body hair loss is escitalopram.
Drug-induced telogen effluvium is a common cause of rapid, diffuse hair shedding triggered approximately three months after starting certain drugs, including antidepressants such as escitalopram NICE CKS. This condition affects both scalp and body hair, although scalp involvement may be less apparent in men with advanced male pattern baldness, manifesting more prominently on body hair as in this patient NICE CKS,NICE CKS.
Rosuvastatin, a statin, is associated more with musculoskeletal adverse effects such as myopathy and arthralgia, which could explain the hip pain but is less frequently linked to rapid hair loss NICE CKS. Mirabegron has no strong evidence associating it with hair loss NICE CKS.
The long-term prostate medications (alfuzosin, dutasteride) and other chronic drugs (verapamil, clonazepam) are less likely contributors because the recent hair loss started after initiation of the new medications and these have been used for over a year without such symptoms NICE CKS. Dutasteride, in particular, usually helps prevent hair loss by inhibiting DHT NICE CKS.
While alopecia areata (AA) is an autoimmune cause of non-scarring hair loss, its presentation typically involves patchy or total scalp hair loss and may be accompanied by immune conditions or triggers like infection or inflammation Młyńska et al. 2026 Abou Samra 2026. There is no specific evidence suggesting AA in this patient, and the rapid diffuse body hair loss timeline fits drug-induced telogen effluvium better NICE CKS Młyńska et al. 2026.
Therefore, among the recent medications started, escitalopram is the most plausible cause of the rapid bodily hair loss due to its known association with telogen effluvium NICE CKS,NICE CKS.
Key References
- NICE CKS: Male pattern hair loss (male androgenetic alopecia)
- NICE CKS: Female pattern hair loss (female androgenetic alopecia)
- SmPC: Minoxidil 5% w/v cutaneous spray, solution
- SmPC: Regaine for Women Once a Day Scalp Foam 5% w/w Cutaneous Foam
- (Młyńska et al., 2026): Alopecia Areata - Effects of Treatment with Upadacitinib - Two Case Reports.
- (Abou Samra and Aboujaoude S., 2026): Dental Rehabilitation of a Child Diagnosed With Alopecia Areata Totalis: A Case Report.
- (Gulsoy and Özdemir Kol İ., 2026): The Effects of Nursing Care Applied in the Intensive Care Unit on a Case of Toxic Epidermal Necrolysis: A Case Report.